Результаты поиска

[Child and adolescent bipolar disorder].

The onset of bipolar disorders before the age of 10 is rare. First manifestation occurs most frequently between the age of 15 to 30. Children of a parent with bipolar disorder are at a fivefold risk for developing a bipolar disorder. Therefore, an elaborate family-history is essential for the assessment of potentially manic or depressive symptoms in children and adolescents. Basically, for all age groups the same diagnostic criteria according to ICD 10 are applied. Due to the differing symptoms for children and adolescents the finding of a diagnosis is considerably harder than for adults. Mani

[Early detection of psychotic disorders].

UNLABELLED: Over the last decade there has been considerable interest in early intervention in schizophrenia and other psychotic disorders, driven by observations that early intervention might favorably alter the course of illness. New clinical and research programs have been established around the globe aiming to reduce treatment delays in psychosis and, more recently, to identify and possibly treat individuals in the pre-psychotic phase who are at imminent risk of developing psychosis. Since May 2004, a service for individuals at high risk (HR) for psychosis has been established at Vienna Ge

[Are there substantial reasons for contraindicating antidepressants in bipolar disorder? Part III. The alternatives!].

After having described depressive symptoms along the course and different subtypes of bipolar disorder the authors focus on pharmacological alternatives to antidepressant medication in bipolar depression. In doing so, they review the newest literature on efficacy of antidepressants and compare effect size of the different alternatives like antipsychotics and mood stabilizers to those of antidepressants. Efficacy of antidepressants in bipolar depression is still discussed controversially, as scientific evidence, is as far as available, weak. Severity of depressive symptoms should define, wether

[Lithium and bipolar disorder--a renaissance?].

OBJECTIVE: Overview and discussion regarding the use and relevance of lithium as an therapeutic agent for bipolar disorder in general, with a special focus on pregnancy, suicidality and possible side-effects. METHOD: Literature was handsearched and by searches of medline with special interest in recent results and comparative studies. RESULTS: Lithium is still of high importance in the treatment of bipolar disorder. It is unmatched regarding decades of clinical experience and scientific evidence. It has a proven efficacy in every spectrum of bipolar illness, with less profound data regarding

[The economics of mental health and health care- a blind spot?].

Mental disorders are associated with an immense burden of disease for patients, their social environment and for society as a whole. Neuropsychiatric diseases have been estimated to account for 27% of disability adjusted life years (DALYs) in the Euro-A region and have thus more impact on the global burden of disease than cardiovascular diseases or neoplasms. In the population younger than 30 years even 65% of years lost due to disability are due to neuropsychiatric disorders. Moreover, the economic consequences of mental disorders pose a significant challenge on health care systems. For examp

Использование микробиомных средств для совершенствования методов лечения нейродегенеративных заболеваний: данные о воздействии вдоль оси микробиота-гут-мозгов.

Недавно в качестве полезной модели для понимания возникновения и развития нейродегенеративных заболеваний (НДД) появилась ось микробиота-гут-мозгов (МГБА). Меры воздействия на основе микробиома с использованием биотических добавок (пробиотики, предбиотики, синдиотики, постбиотики) могут модифицировать MGBA и служить подходящими решениями для снижения риска неврологических изменений, связанных с НИЗ, и регулирования симптомов. В настоящем описательном обзоре содержится резюме функционирования МГБС и его взаимодействия с заболеваниями, связанными с началом и развитием НИЗ. Проводится обзор мероп

Amyloid Proteins and Peripheral Neuropathy.

Painful peripheral neuropathy affects millions of people worldwide. Peripheral neuropathy develops in patients with various diseases, including rare familial or acquired amyloid polyneuropathies, as well as some common diseases, including type 2 diabetes mellitus and several chronic inflammatory diseases. Intriguingly, these diseases share a histopathological feature-deposits of amyloid-forming proteins in tissues. Amyloid-forming proteins may cause tissue dysregulation and damage, including damage to nerves, and may be a common cause of neuropathy in these, and potentially other, diseases. He

Совпадение в полном тексте источника
… Neuropsychiatry 2019 56 150 156 10.29399/npa.23502 PMC6563867 31223250 40. Plante-Bordeneuve V. Said G. Familial amyloid polyneuropathy Lancet Neurol. 2011 10 1086 1097 10.1016/S1474-4422(11)70246-0 22094129 41. Waddington-Cruz M. Ackermann E.J. Polydefkis M. Heitner S.B. Dyck P.J. Barroso F.A. …

Резюме докладов 53rd Конференция Европейского общества генетики человека: интерактивные электронные постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Pizzuti 1 1 Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, 2 Laboratory of Medical Genetics, Ospedale Pediatrico Bambino Gesù, Rome, Italy, 3 Department of Maternal and Child Health and Urologic Science, Sapienza University of Rome, Rome, Italy, 4 Pediatrics and Child Neuropsychiatry …

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation.

The premutation of the fragile X messenger ribonucleoprotein 1 (FMR1) gene is characterized by an expansion of the CGG trinucleotide repeats (55 to 200 CGGs) in the 5' untranslated region and increased levels of FMR1 mRNA. Molecular mechanisms leading to fragile X-premutation-associated conditions (FXPAC) include cotranscriptional R-loop formations, FMR1 mRNA toxicity through both RNA gelation into nuclear foci and sequestration of various CGG-repeat-binding proteins, and the repeat-associated non-AUG (RAN)-initiated translation of potentially toxic proteins. Such molecular mechanisms contribu

Current landscape of innovative drug development and regulatory support in China.

The global pharmaceutical landscape remains dynamic and competitive, shaped by advancements in first-in-class therapies and breakthrough technologies. The United States has maintained its leadership in first-in-class therapies and breakthrough technologies, driven by advanced regulatory pathways, significant multinational corporation investments, a robust Research and Development (R&D) workforce, and continuous technological innovation. Additionally, global impact of the Food and Drug Administration (FDA) is further amplified through collaborations like Project Orbis, which facilitates simulta

Совпадение в полном тексте источника
… Additionally, two TCM products for dermatology and otorhinolaryngology were approved, along with one product each in the fields of gastroenterology, respiratory medicine, and neuropsychiatry. 95 A comprehensive inventory of Category 1 innovative drugs approved by the NMPA from 2018 to 2023 is shown …

Purinergic Signalling: Therapeutic Developments.

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990's when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and the

Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: e-Posters.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Специальный выпуск: резюме 11th Конгресс Европейской академии неврологии, Хельсинки, Финляндия.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме докладов 51st Конференция Европейского общества генетики человека: плакаты

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ePoster.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts of the 19th International Congress on Neuromuscular Diseases 7th – 11th July 2026

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

АКНП 60th Ежегодное совещание: выдержки из плакатов P276 - P550.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 2.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 28th Европейский конгресс педиатрической ремуматологии (ПСР) 2022) Прага, Чешская Республика. 20-23 сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 25th Европейский конгресс педиатрической ремуматологии (ПСР) 2018) Лиссабон, Португалия. 5-8 сентябрь 2018

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.